Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma

NCT05578170 · clinicaltrials.gov ↗

UNKNOWN

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab

Sponsor

Nanfang Hospital, Southern Medical University